SMASH: Safety of Mechanical Insufflation-exsufflation and Hypertonic Saline

Sponsor
Hospital San Carlos, Madrid (Other)
Overall Status
Completed
CT.gov ID
NCT03940118
Collaborator
Chiesi España (Other), Philips Respironics (Industry)
120
1
4
10.9
11

Study Details

Study Description

Brief Summary

Conventional catheter suctioning of respiratory tract secretions is a mandatory procedure in intubated patients. Poor tolerance, pain and other, sometimes severe, lung and cardiovascular complications may occur during suctioning.

Mechanical insufflation-exsufflation (MIE), coupled with hypertonic saline (HS), may improve efficacy airway clearance and reduce risk of the maneuver. However, safety of MIE and HS in intubated patients have not been studied appropriately, which justifies a randomized evaluation compared to conventional secretion suctioning.

Condition or Disease Intervention/Treatment Phase
  • Device: Catheter secretion suctioning
  • Combination Product: Secretion suctioning + hypertonic saline
  • Device: Ins-exsufflation
  • Combination Product: Ins-exsufflation + Hypertonic saline
N/A

Detailed Description

Secretion suctioning (SS) in patients with artificial airway is a mandatory procedure, although occasionally painful, not tolerated and even causing traumatic injury to the respiratory mucosa.

Mechanical insufflation-exsufflation (MIE) and nebulized hypertonic saline with hyaluronic acid (HS-HA) have shown efficacy and safety in patients with chronic neuromuscular and pulmonary diseases, achieving aspiration and fluidification of respiratory secretions, respectively, as well as good tolerance.

Only anecdotal experience about the safety of MIE and HS-HA in critically ill patients with artificial airway and mechanical ventilation is available.

Background: Both MIE and HS-HA facilitate the drainage of secretions from the distal airway (compared to conventional catheter suctioning, the effect of which is supposed to be limited to the trachea) Both measures may prove to be efficacious in the prevention (through airway clearance of secretions) and concomitant treatment (reduction of inoculum or "draining the lung") of lower respiratory tract infections (tracheobronchitis and pneumonia).

Study Design

Study Type:
Interventional
Actual Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Intervention Model Description:
Randomized, four groups of different respiratory tract secretion suctioning methods: 1) catheter (conventional), 2) catheter after hypertonic saline, 3) mechanical insufflation-exsufflation, and 4) mechanical insufflation-exsufflation with hypertonic salineRandomized, four groups of different respiratory tract secretion suctioning methods: 1) catheter (conventional), 2) catheter after hypertonic saline, 3) mechanical insufflation-exsufflation, and 4) mechanical insufflation-exsufflation with hypertonic saline
Masking:
Single (Investigator)
Masking Description:
Closed envelop to be opened after inclusion/exclusion criteria are met and informed consent obtained
Primary Purpose:
Other
Official Title:
A Randomized Study on the Safety and Tolerability of Mechanical Insufflation-exsufflation and Hypertonic Saline With Hyaluronic Acid for Suctioning of Respiratory Tract Secretions in Patients With Artificial Airway
Actual Study Start Date :
Jun 1, 2018
Actual Primary Completion Date :
Apr 30, 2019
Actual Study Completion Date :
Apr 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Catheter secretion suctioning

Secretions are aspirated with a catheter at -120 to -150 mBar

Device: Catheter secretion suctioning
Catheter secretion suctioning with prior nebulization of hypertonic saline

Experimental: Secretion suctioning + hypertonic saline

Hypertonic saline is nebulized prior to aspiration of secretions.

Combination Product: Secretion suctioning + hypertonic saline
Catheter secretion suctioning with prior nebulization of hypertonic saline

Experimental: Ins-exsufflation

Mechanical insufflation-exsufflation with device programmed at 50/-50 mmHg

Device: Ins-exsufflation
Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning

Experimental: Ins-exsufflation + Hypertonic Saline

Mechanical insufflation-exsufflation and hypertonic saline

Combination Product: Ins-exsufflation + Hypertonic saline
Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning

Outcome Measures

Primary Outcome Measures

  1. Aggregate cardiovascular and respiratory adverse events of mechanical insufflation-exsufflation and hypertonic saline. [1 hour]

    Comparative incidence of aggregate hemodynamic and respiratory adverse events. Adverse events criteria are predefined and will be expressed as: Percentage of patients meeting aggregate predefined hemodynamic or respiratory adverse event criteria per study group. Percentage of specific predefined adverse events (outcome variable "yes" or "no"): Desaturation (pulse-oximetry, >5%), hemoptisis (yes or no), bronchospasm (needing bronchodilator therapy), pneumothorax (as assessed by chest X-ray), hypotension (>30% or >10% increase in noradrenaline infusion from baseline), hypertension (>30% or >10% decrease in noradrenaline infusion from baseline), tachycardia (>90 bpm or >30% increase), bradycardia (<40 bpm), arrythmias (supra ventricular, requiring therapy), atelectasis (as assessed by chest X-ray), and other complications occuring during or within 1 hour after the procedure.

  2. Pain score during mechanical insufflation-exsufflation and hypertonic saline as assessed by quantitative a pain scoring systems. [1 hour]

    Comparative pain scores of the study procedures in the 4 study groups will be assessed using the "ESCID" pain score (EScala de Conductas Indicadoras de Dolor, ranging from 0, no pain, to >6, intense pain, see citations) at baseline, during the procedure and at 5 and 60 minutes after the aspiration of respiratory secretions. Both comparison of the score at the 4 study time-points and their variations between time-points will be analysed.

  3. Sedation/agitation score during mechanical insufflation-exsufflation and hypertonic saline as assessed by a quantitative sedation/agitation system. [1 hour]

    Comparative sedation/agitation score of the study procedures in the 4 study groups will be assessed using the RASS (Richmond Agitation-Sedation Scale, see citations), range -5, un-arousable, to +5, combative) at baseline, during the procedure and at 5 and 60 minutes after the aspiration of respiratory secretions.

  4. Sedation/responsiveness score during mechanical insufflation-exsufflation and hypertonic saline as assessed by quantitative a sedation scoring system. [1 hour]

    Comparative sedation/responsiveness score of the study procedures in the 4 study groups will be assessed using the responsiveness "Ramsay" Sedation Scale, range from 1, anxious and agitated, to 6, no response to stimulus, see citations) at baseline, during the procedure and at 5 and 60 minutes after the aspiration of respiratory secretions.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Artificial airway ( endotracheal tube or tracheostomy cannula) with pressure cuff.

  • Need for aspiration of secretions

  • Informed consent

Exclusion Criteria:
  • Macroscopic hemoptysis.

  • Acute bronchospasm

  • Uncrontrolled muscular contractions, like tremor, myoclonus or other.

  • Confirmed pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Clinico San Carlos Madrid Spain 28040

Sponsors and Collaborators

  • Hospital San Carlos, Madrid
  • Chiesi España
  • Philips Respironics

Investigators

  • Principal Investigator: Miguel Sanchez Garcia, MD, PhD, Hospital Clinico San Carlos

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Miguel Sanchez Garcia, Director Critical Care. MD. PhD., Hospital San Carlos, Madrid
ClinicalTrials.gov Identifier:
NCT03940118
Other Study ID Numbers:
  • 18/253-R_X
First Posted:
May 7, 2019
Last Update Posted:
May 8, 2019
Last Verified:
May 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Miguel Sanchez Garcia, Director Critical Care. MD. PhD., Hospital San Carlos, Madrid

Study Results

No Results Posted as of May 8, 2019